Targeted combination therapy for glioblastoma by co-delivery of doxorubicin, YAP-siRNA and gold nanorods

Li Lihuang,Guo Qiuyan,Liu Yanxiu,Lu Mindan,Yang Jun,Ge Yunlong,Zhang Qiang,Sun Benqiang,Wang Xiumin,Li Liang-cheng,Ren Lei

DOI: https://doi.org/10.1016/j.jmst.2020.03.009

IF: 10.319

2021-02-01

Journal of Materials Science and Technology

Abstract:The combination of brain targeting drug delivery systems and multi-modal intervention pose a promising therapeutic approach for glioblastoma therapy. In this study, we developed an angiopep-2 peptide modified cationic liposome loaded with doxorubicin, YAP-siRNA and gold nanorods (D/ + Au) simultaneously, which has high encapsulating efficiency for doxorubicin (95.4%) and effective binding of siRNA at N/P ratio of 20:1. The fluorescence imaging and flow cytometry analysis revealed high cellular uptake of D/ + Au. Real-time quantitative polymerase chain reaction and western blot analysis indicated that D/ + Au could effectively inhibit the expression of YAP protein. In vitro and in vivo studies showed that D/ + Au had the ability to target glioblastoma cells, and achieved better anti-proliferative effects compared with non-targeted D/ + Au. Moreover, in vivo experiment demonstrated that D/ + Au was able to cross the blood-brain barrier, and combination therapy could significantly inhibit tumor growth. Therefore, the multifunctional D/ + Au might provide a novel approach for effectively delivery of DOX, YAP-siRNA and AuNRs into the glioblastoma cells simultaneously and exerting synergistic therapeutic effects.